Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_4
3
60%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Other(1)

Detailed Status

Completed3
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (20.0%)
Phase 43 (60.0%)
N/A1 (20.0%)

Trials by Status

completed360%
recruiting120%
unknown120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingnot_applicable

Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy

NCT07479056
completedphase_4

Helicobacter Pylori Eradication Study

NCT03130452
completedphase_3

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

NCT05448001
unknownphase_4

Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)

NCT04660461
completedphase_4

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

NCT00410592

Clinical Trials (5)

Showing 5 of 5 trials
NCT07479056Not Applicable

Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy

Recruiting
NCT03130452Phase 4

Helicobacter Pylori Eradication Study

Completed
NCT05448001Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Completed
NCT04660461Phase 4

Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)

Unknown
NCT00410592Phase 4

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5